TY - JOUR
T1 - The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
AU - Ma, Brigette B.Y.
AU - Sung, Fion
AU - Tao, Qian
AU - Poon, Fan Fong
AU - Lui, Vivian W.
AU - Yeo, Winnie
AU - Chan, Stephen L.
AU - Chan, Anthony T.C.
N1 - Funding Information:
Acknowledgements This study was sponsored by the Cancer Therapy Evaluation Program of the National Cancer Institute (Bethesda, USA). Result of this study was presented as a poster at the 98th American Association of Cancer Research annual meeting in April 2007, Los Angeles; abstract number 2494. This study was funded by the Direct Grant of the Chinese University of Hong Kong (Reference 2005.1.018), and the Li Ka Shing Institute for Health Sciences.
PY - 2010/4
Y1 - 2010/4
N2 - The activity of the histone deacetylase inhibitor PXD101 was investigated in three hepatocellular carcinoma (HCC) cell lines. PXD101was found to inhibit cell growth at a dose-dependent manner and induce histone acetylation in PLC/PRF/5, Hep3B and HepG2 cells. In PLC/PRF/5 and Hep3B cells which express hepatitis B-related genes (HBx, HBc and HBc), treatment with PXD101 resulted in apoptosis without a significant effect on viral gene expression. Exposure to PXD101 for up to 48 h had varying effects on the expression of 12 cellular genes with tumor suppressor functions, including p21, SOCS1, CMTM5, RASAL1, DLEC1, SFRP (-1, -2, -4 and -5), ADAMTS (-8 and -9). This study provided the basis for a phase II clinical trial of PXD101 in inoperable hepatitis-B associated HCC.
AB - The activity of the histone deacetylase inhibitor PXD101 was investigated in three hepatocellular carcinoma (HCC) cell lines. PXD101was found to inhibit cell growth at a dose-dependent manner and induce histone acetylation in PLC/PRF/5, Hep3B and HepG2 cells. In PLC/PRF/5 and Hep3B cells which express hepatitis B-related genes (HBx, HBc and HBc), treatment with PXD101 resulted in apoptosis without a significant effect on viral gene expression. Exposure to PXD101 for up to 48 h had varying effects on the expression of 12 cellular genes with tumor suppressor functions, including p21, SOCS1, CMTM5, RASAL1, DLEC1, SFRP (-1, -2, -4 and -5), ADAMTS (-8 and -9). This study provided the basis for a phase II clinical trial of PXD101 in inoperable hepatitis-B associated HCC.
KW - Hepatitis B
KW - Hepatocellular carcinoma
KW - PXD101
KW - Tumor suppressor genes
UR - http://www.scopus.com/inward/record.url?scp=77952240320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952240320&partnerID=8YFLogxK
U2 - 10.1007/s10637-009-9219-7
DO - 10.1007/s10637-009-9219-7
M3 - Article
C2 - 19172229
AN - SCOPUS:77952240320
SN - 0167-6997
VL - 28
SP - 107
EP - 114
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 2
ER -